"The results, which were published in the Lancet on Thursday, are very encouraging for the safety and efficacy of orforglipron in people with type 2 diabetes, says Daniel Drucker, an endocrinologist at the University of Toronto, adding that he is awaiting further clinical trial results of the drug in people with obesity."
"Orforglipron is a once-a-day pill that acts on glucagonlike peptide 1 (GLP-1) receptors. The injectable GLP-1 drugs Zepbound and Mounjaro are also made by Eli Lilly. Oral semaglutide has been on the market to treat type 2 diabetes since 2019."
"More options for people with these challenging diseases will be very helpful, particularly if the new oral tablet medicines are priced reasonably, he says. Now orforglipron is inching closer to becoming the next oral option to be approved in the U.S."
A clinical trial published in the Lancet compared orforglipron, an oral GLP-1 receptor agonist developed by Eli Lilly, against oral semaglutide from Novo Nordisk in 1,698 people with type 2 diabetes. After 52 weeks, the 36-milligram dose of orforglipron showed greater reductions in blood sugar and weight compared to oral semaglutide doses. Orforglipron is a once-daily pill that represents a new oral option for diabetes and weight management. Experts note that additional oral GLP-1 medications provide more treatment choices for patients, particularly if priced affordably. The results support orforglipron's safety and efficacy profile as it progresses toward potential FDA approval for obesity treatment.
#glp-1-receptor-agonists #type-2-diabetes-treatment #weight-loss-medications #clinical-trial-results #oral-diabetes-medications
Read at www.scientificamerican.com
Unable to calculate read time
Collection
[
|
...
]